This company has shut down. S2 Genomics is no longer operating — its last tracked round was a Series A in 2024.
Explore the Startup GraveyardS2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
S2 Genomics has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
S2 Genomics's investors include HealthTech Capital, Life Science Angels, BroadOak Capital Partners, Research Corporation Technologies.
S2 Genomics is headquartered in Livermore, United States.
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
S2 Genomics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"S2 Genomics — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/s2-genomics. Accessed August 1, 2026.
VCBacked. (2024). S2 Genomics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/s2-genomics
{{cite web |title=S2 Genomics — Funding & Investors |url=https://www.vcbacked.co/company/s2-genomics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated